Is Akebia Therapeutics Inc (AKBA) a Stock to Watch After Gaining 6.06% This Week?

The market has been high on Akebia Therapeutics Inc (AKBA) stock recently. AKBA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Akebia Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AKBA!

See Full AKBA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AKBA Stock Today?

Akebia Therapeutics Inc (AKBA) stock is higher by 4.5% while the S&P 500 is down -0.22% as of 1:50 PM on Thursday, Nov 30. AKBA has gained $0.04 from the previous closing price of $1.00 on volume of 1,204,222 shares. Over the past year the S&P 500 is higher by 14.73% while AKBA has gained 320.00%. AKBA lost -$0.33 per share in the over the last 12 months.

More About Akebia Therapeutics Inc

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Click Here to get the full Stock Report for Akebia Therapeutics Inc stock.